Atrium Therapeutics, Inc.
RNA
NASDAQ·Healthcare·Biotechnology·Mkt cap $242.7M
$14.19
▼ -2.81%
P/E
-2.77
Mkt Cap
$242.7M
52-Wk Range
$11.13–$16.77
52-Week Range
$11.13 - $16.77
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 3.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AOC platform enabling targeted muscle tissue delivery
- First-mover advantage in oligonucleotide-antibody conjugate technology
- Focused pipeline addressing high-unmet-need rare monogenic diseases
- Established commercial infrastructure through Lumizyme distribution
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Clinical advancement of AOC 1001 for myotonic dystrophy type 1
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+22.9% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$1.18 vs -$1.42 consensus (+16.9% surprise). Revenue of $3.0M vs $666.7K expected (+350.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.9%
Revenue trend · last 8Q
—
+36%
-56%
+88%
+434%
-71%
+1148%
-22%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.3M
$3.0M
$1.6M
$3.8M
$12.5M
$859.0K
$19.6M
$3.0M
Margins · last 8Q
Gross
88.6%
Profit
-672.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 6, 2026
vs Industry
How RNA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related